Stuart Poulton - Feb 28, 2024 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role
EVP, Chief Development Officer
Signature
/s/Nancy Smith as Attorney-in-Fact for Stuart Poulton
Stock symbol
KPTI
Transactions as of
Feb 28, 2024
Transactions value $
$0
Form type
4
Date filed
2/29/2024, 05:35 PM
Previous filing
Feb 20, 2024
Next filing
Mar 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KPTI Common Stock Award $0 +188K +114.92% $0.00 352K Feb 28, 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2025.